OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) And STENOCARE Sign An MOU

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) and STENOCARE are into a new progressive deal. The two business giants just moved into a Memorandum of Understanding (MoU) that is quite strategic. These two seek to engage in the development and the commercialization of some wide-ranging cannabis-based medical products.

Terms of the deal

Each of the parties will have something to gain from the deal. For instance, OWC’s technologies will benefit from a more expansive market. On the other hand, the business strategy of STENOCARE might end up becoming a huge success. The business guru has been looking forward to supplementing its top-quality generic medical cannabis products. Its target has been to supplement them with differentiated products meant to treat numerous patient groups struggling with particular serious conditions.

The new cooperation means well for them, considering that they will increase their sales massively. They will also be able to distribute products in large volumes within the existing core markets of STENOCARE. The businesses also want to venture into new territories in their quest to boost their business profits.

STENOCARE and its plans

STENOCARE expresses its willingness to deliver some top quality cannabis raw materials. Asides from that, it will also be seeking to provide extensive knowledge in line with the supply and the distribution of the medical cannabis-based products in Ireland and Denmark as well.

On the other hand, OWC Pharmaceutical says it will offer its expertise in clinical trials and medical research. The business has been focusing on cannabis products providing therapeutic solutions to patients. It prides itself on having in place what it terms an extensive Intellectual Property Portfolio.

The first product candidate

The information regarding the first product candidate for this collaboration is already out. This will be a sublingual tablet pulling along with specified medical cannabis ratios vital in meeting up to the needs of patients. It will be important to make the appropriate diagnosis as well as check out how they will be responding to treatment.

The CEO of OWC Pharmaceutical Research Mordechai Bignitz says that STENOCARE is a great choice for a partner. He says that considering the company’s capacity in the distribution of medical cannabis products to some interesting markets. This official also speaks about the focus on pharma-grade production.


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Announces Positive Safety Results From The First Phase Study For Medical Cannabis Ointment For Skin Disease Treatment

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has announced positive safety data for the first phase study of the medical grade cannabis ointment in treating skin diseases.

Preliminary results indicate that there were no severe adverse effects observed in the safety study. OWC Pharmaceuticals is on track to commence the second phase MSG ointment trial by the third quarter of 2019 in the treatment of psoriasis.

The first phase study was a single center, placebo-controlled trial for the assessment of tolerability and safety of the Cannabis MGC ointment in healthy subjects. The ointment has 3% THC and 3% CBD components. The study was carried out in Israel at the Sheba Academic Medical Centre from September 2017 when the first subject was enrolled in the study until January this year when the last subject concluded the trial.

Stages of the study

The first stage was designed for the evaluation of safety and tolerability after a single dose administration of MGC ointment 26 volunteers. The subjects got hospitalized and they were monitored 24 hours.

The second stage was equally designed to evaluate the safety and tolerability of the MGC ointment after repeated application in 20 volunteers for almost six weeks. The second stage enrolled 7 new subjects in addition to 20 of those who participated in the first stage. The application of the MSG ointment was to be done by the subjects at home twice each day. The subjects were to apply the MGC ointment on one arm and then the MSG on the other placebo arm.

No adverse effects from MSG and MGC ointment

There were no adverse events reported in the two stages of the study although one subject reported minor irritations.

CEO Mordechai Bignizt indicated that they were motivated by the positive results from the first phase of the trial. He added that this was the first study that evaluated the safety and tolerability of their medical grade cannabis ointment as a topical skin disease treatment.

The second phase of the trial of MSC ointment will commence in the Q3 2019 for treatment of psoriasis.


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Issues Chairman’s Statement to Shareholders

The Owc Pharmaceutical Research Corp. (OTCMKTS:OWCP) which a leading developer of cannabinoid based therapies that targets a large variety of condition and disorders medicines.

The company is willing and committed in structuring itself as a leader in the cannabis medical market and to improve its patients’ lives by development of a new solution together with devices and other products.

New Events

The products are said to have been derived from mechanisms that are used in the delivery of cannabis in the medical sector.

The company has recruited a high number of skilled managers in their team who have an experience in the cannabis medical sector, pharmaceutical development and management of cooperatives in togetherness with the capital markets. In a statement the company indicated that it is not a member of the pact that had recently been signed.

The chief executive officer of the company in a statement given to newsrooms said that it is aimed at developing the programs, which are set to be rolled out by the organization in few months to come.

Safety Tests

In the program there is safety test for the cannabis cream that is inter alia. The process to be approved needs an initiative safety trial for all the tablets and other pipeline projects to be added. The company is said to be gearing toward the improvement of the shareholders stake through a professional, ethical and management strategy.

With all these put in place the company has continued to offer better and high quality products to its existing and upcoming customers. There are also some changes which will be put in place in the management of the company to reduce chances of a fallout. The management also stated that it was committed to development programs.

Dr. Stanley Hirsch, the company’s chairman attributed to the fact that the management was committed to building value for its shareholders through strategic, professional and ethical management that is believed to bring improved health and quality of life to patients around the world.


SinglePoint, Inc. (OTCMKTS:SING) Targets Cannabis Industry with Safe, Secure, and Convenient Payment Processing via Cryptocurrencies

SinglePoint, Inc. (OTCMKTS:SING) has been providing the cannabis industry with a variety of services through its SingleSeed subsidiary over the past several years, but they are preparing their greatest service to the industry yet: cryptocurrency payment processing support.

The cannabis industry is under constant threat of federal regulation, which makes traditional financial institutions like banks hesitant to work with cannabis businesses. SinglePoint is developing a payment processing solution that deals with Bitcoin and Ethereum, which provides transparency, security, speed, and convenience to handling payments, as well as giving companies a place to keep their hard-earned revenue. The cannabis industry has been largely cash-based for years, and this creates security threats. Virtual payment options, backed by the ledger that blockchains provide, will be able to protect many of these businesses from the threat of being robbed for their cash in person. It will also provide in-depth records on each transaction and help protect businesses in the event of an IRS audit.

With SinglePoint filling the payment processing gap with a safe and secure solution, they could quickly gain steam as the de facto standard for how cannabis industry payments are made. The company has already begun work on its Bitcoin processing framework, having started developing a solution back in 2014. They just engaged a recruiting firm from the bay area of San Francisco to help hire top Bitcoin software engineers. This will expedite the launch and help SinglePoint fill the market need before another company has the opportunity to step up to the challenge.

Notable Cannabis stocks to watch include the north american marijuana industry players such as Cannabis Sativa Inc (OTCMKTS:CBDS), United Cannabis Corp (OTCMKTS:CNAB), OWC Pharmaceutical Research Corp (OTCMKTS:OWCP), Cannabis Science Inc (OTCMKTS:CBIS), and Marijuana Company Of America Inc (OTCMKTS:MCOA) take advantage of a bitcoin-based payment systems, but also Canadian marijuana companies such as AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF), APHRIA INC COM NPV (OTCMKTS:APHQF), NEW AGE FARM INC COM NPV (OTCMKTS:NWGFF), and CANOPY GROWTH CORP COM NPV (OTCMKTS:TWMJF) could pioneer in the emerging Marijuana financial sector.


Bitcoin and Cannabis: Where the Action Is

A trader’s job is never easy. That’s true almost by definition. But one key lesson that most every trader learns quickly is: Go where the action is. 2017 has been an interesting year thus far. Our job today is to take a closer look at two of the most interesting and most talked-about market spaces: Cannabis and Bitcoin. But first, let’s put things into context.

The year got started with one theme dominating the action: the recent election of Donald Trump as the 45th President of the United States of America. That event completely redefined global financial markets as investors began to anticipate a strong-handed push for widespread deregulation, huge tax reforms, and a massive infrastructure-centric fiscal stimulus meant to supercharge economic growth. The markets also shifted in anticipation of a US trade policy geared toward protectionism and a “zero-sum” view of global relationships – ie, that there are winners and losers, rather than better versus worse global outcomes. It’s a bit like going from a mentality that concerns itself with the size and quality of a pie to one that concerns itself with how big a slice we get on our plate.

However, while all of that stuff was dominating the headlines in the Wall Street Journal and Financial Times, two other trends were starting to take over the spotlight among small cap growth investors.

On the same day that the crown was pressed down on Trump’s head, 9 states went to the ballot boxes in the US to vote on marijuana legislation, with 8 of them passing measures to drastically increase the legality of marijuana use across the US. We saw this rally power most of the leading plays in the space, including Cannabis Sativa Inc (OTCMKTS:CBDS), United Cannabis Corp (OTCMKTS:CNAB), OWC Pharmaceutical Research Corp (OTCMKTS:OWCP), Cannabis Science Inc (OTCMKTS:CBIS), and Marijuana Company Of America Inc (OTCMKTS:MCOA).

Several weeks later, investors learned that legislation was coming in Canada to fully legalize marijuana for both medical and recreational use on a nationwide basis. That most directly impacted a number of leading Canadian cannabis plays, such as AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF), APHRIA INC COM NPV (OTCMKTS:APHQF), NEW AGE FARM INC COM NPV (OTCMKTS:NWGFF), and CANOPY GROWTH CORP COM NPV (OTCMKTS:TWMJF), among others.

That news formed the backdrop for some truly explosive action among a broad group of stocks in the cannabis patch.

Now, it seems as though we are starting to see some similar action for stocks involved in the Bitcoin market space. The value of Bitcoins, in dollar terms, has exploded higher, nearly tripling in the past 3 months. And several related stocks and asset plays are ripping right along with it. The best way to gauge (or, indeed, to impact) interest in any security is through allocation. And this is often a two-way street: allocation grows as accessibility increases; and accessibility increases as interest (allocation) grows.

It’s what we call a “self-reinforcing feedback loop”. That’s what we are seeing here between bitcoin and Bitcoin Investment Trust (OTCMKTS:GBTC). In fact, as we see it, the marketing work has been done sufficiently to get the process of that feedback loop going. All that’s necessary is a vehicle with tons of liquidity and accessibility, and public allocation (and interest) in bitcoin will have an avenue of mass appeal and growth.

GBTC is making a bid to be that vehicle with an active application to become an official “commodity trust Exchange Traded Product”. Will regulators finally allow a super accessible big board bitcoin ETF?

The last two such attempts were thwarted for a very specific reason: The SEC has ruled repeatedly that a commodity trust, in order to qualify as a potential exchange traded product, must have two characteristics.

First, it must have surveillance-sharing agreements in place if it is an international asset (which bitcoin most certainly is, and which bitcoin most certainly does not). And second, it must be a “regulated” market (which bitcoin is not). Hence, unless a whole lot changes, GBTC will not IPO as a big board Bitcoin ETF. That said, for many average investors and market participants, there simply isn’t an easy way to feel comfortable betting on Bitcoin. And GBTC allows for such a move.

There are a few other accessible Bitcoin stocks to watch as well: BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC), FIRST BITCOIN CAP COM NPV(OTCMKTS:BITCF), WPCS International Incorporated (NASDAQ:WPCS), UBI Blockchain Internet Ltd (OTCBB:UBIA), and MGT Capital Investments Inc. (OTCMKTS:MGTI).


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Topical Cream In Focus

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has obtained expressions of interest from the medical and scientific communities globally as a result of its recently reported positive initial clinical efficacy tests data of its topical cream targeting Psoriasis.

The details

OWC Pharmaceutical’s scientific team, directed by the famous Dr. Yehuda Baruch, the firm’s Chief Science Officer previously released trial data and stated that post-application of company’s unique, active CBD-based topical cream, they recorded up to 70% improvement in many inflammation markers directly linked with Psoriasis.

This promising data have led them to expand the scope and size of its clinical study and has resulted in directly to receipt of continuing queries and expressions of interest from investigators world-wide for more data on its topical cream for psoriasis treatment and their product’s expected availability for application in the market.

OWC Pharmaceutical actively protects its IP. It will report the final data, clinical data and relevant protocols after the closure of the full bio-data IP protection. Ziv Turner, the Managing Director of OWC Pharmaceutical, commented that as soon as they closed the efficacy results of their pre-clinical psoriasis cure, the company has continued to get active inquiries from many global scientific institutions in nations like Germany, Hungary, the Czech Republic, and more, that adopted or plan to adopt MMJ bills.

The company is in talks for marketing and scientific cooperation deals. In addition, they realistically anticipate product readiness for their topical cream in initial Q3 2017 and, based on regulatory approvals, states and federal laws they can offer their product to psoriasis patients.

Psoriasis comes in the list of autoimmune diseases, and a patient with psoriasis gets red, scaly patches on the skin. The disease can be related with other grave health conditions, including heart disease, depression and diabetes. Skin cells in psoriasis patients grow at an unusually fast rate, triggering a buildup of lesions that burn and itch.

Pin It on Pinterest